Inactive/Delisted stock
BriaCell Therapeutics Stock (NASDAQ:BCTX)
Previous Close
$2.93
52W Range
$0.35 - $9.82
50D Avg
$3.52
200D Avg
$2.38
Market Cap
$19.79M
Avg Vol (3M)
$1.55M
Beta
1.70
Div Yield
-
BCTX Company Profile
BriaCell Therapeutics Corp., an immuno-oncology biotechnology company, engages in developing immunotherapies for the treatment of cancer. Its lead candidate is Bria-IMT that is in Phase I/IIa clinical trial in a combination study with immune checkpoint inhibitors for the treatment of breast cancer. The company also has a cooperative research and development agreement with the National Cancer Institute for developing Bria-OTS, a personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test. BriaCell Therapeutics Corp. is headquartered in West Vancouver, Canada.